Autoimmune Association and 50+ Patient Groups Send Letter to Key Members of Congress on Drug Pricing Priorities for Autoimmune Patients
Washington, DC, July 30, 2021 – Autoimmune Association sent a letter to key members of Congress with the undersigned 50+ patient groups on the importance of drug pricing policy concerns, priorities, and solutions for individuals living with autoimmune disease.
At a high-level, the letter focuses on the following concerns;
- Concerns With Foreign-Reference Pricing
- QALY as Discriminatory
- Access Restrictions to Medicines Now, Lack of Future Cures
We also suggest patient-focused policy solutions;
- Counting Copay Assistance Toward Deductible, Out-of-Pocket Caps
- Ensuring Discounts Go Directly to Patient
- Addressing Rebates in the System, Highlighting PBM Practices
Specifically, the letter went to House and Senate leadership, House E&C, Senate HELP, and Senate Finance, and the group of 10 democrats who wrote a letter to Speaker Pelosi regarding concerns for certain drug pricing policies under HR3.
Autoimmune Association is the nation’s only nonprofit organization dedicated to bringing a national focus to autoimmunity as a category of disease and a major women’s health issue and promoting a collaborative research effort in order to find better treatments and a cure for all autoimmune diseases.
For upcoming Autoimmune Association events visit Events Calendar at www.aarda.org. For more information, visit www.aarda.org. Follow us on social media: Facebook, Twitter, LinkedIn, Instagram, and YouTube.
Join our email list
Receive the latest blog articles, news, and more right to your inbox!
Related articles you might be interested in
Autoimmune Association Leads Sign-On Letter, 64 Patient Groups Ask Congress to Protect Rare Disease Drug Development
Autoimmune Association Leads Sign-On Letter for 2023 NBPP Proposed Rule, Highlights Lack of Language Protecting Copay Assistance
Find more resources on autoimmunity
Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.